Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026

About this update from Devonian Health Group, Inc.

Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026 /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial"; color:black; margin:0in; } Canada NewsWire (all amounts are in Canadian dollars)Quarter ended April 30, 2026, net loss of $1.9 million dollars, ($0.70) per shareNine months ended April 30, 2026, net loss of $5.7 million dollars, ($2.07) per shareCash as of April 30, 2026, $0.7 millionCompany remains debt-freeQUÉBEC, June 29, 2026 /CNW/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlighted its financial and operating results for the three and nine months ended April 30, 2026. ''We are pleased with the continued momentum to execute on our priorities and readiness to advance our pipeline'', said Dr. André P. Boulet, PhD, Chief Executive Officer and president of Devonian.Corporate HighlightsStrategic Update Company expects to remain highly focused on the development of Thykamine™ in prevention of Radiodermatitis associated to radiotherapy and in the treatment of Atopic Dermatitis in children. Furthermore, the Company will continue to investigate the mechanisms of action of Thykamine™ while advancing the evaluation of its potential as a novel therapeutic candidate for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and fibrotic diseases.Financial HighlightsNet Loss and Comprehensive LossFor the three months ended April 30, 2026, the net loss and comprehensive loss was $1.9 million, $0.70 per share, compared to a net loss and comprehensive loss of $4.8 million, $1.94 per share, for the same period in 2025.This decrease of $2.9 million in net loss and comprehensive loss is mainly related to the $4.8 million impairment loss of intangible assets and Goodwill related to the generic business (Altius) recorded in the prior fiscal year, following the expiry of the distribution agreement related to Dexlansoprazole which is partly offset by higher losses from operations for an amount of $1.9 million.Fo...

View stock analysis, news, and events for Devonian Health Group, Inc.